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Abstract
Context: The goal of influenza vaccination programs is to reduce influenza-associated disease outcomes. Therefore,
estimating the reduced burden of influenza as a result of vaccination over time and by age group would allow for a clear
understanding of the value of influenza vaccines in the US, and of areas where improvements could lead to greatest
benefits.
Objective: To estimate the direct effect of influenza vaccination in the US in terms of averted number of cases, medically-
attended cases, and hospitalizations over six recent influenza seasons.
Design: Using existing surveillance data, we present a method for assessing the impact of influenza vaccination where
impact is defined as either the number of averted outcomes or as the prevented disease fraction (the number of cases
estimated to have been averted relative to the number of cases that would have occurred in the absence of vaccination).
Results: We estimated that during our 6-year study period, the number of influenza illnesses averted by vaccination ranged
from a low of approximately 1.1 million (95% confidence interval (CI) 0.6–1.7 million) during the 2006–2007 season to a high
of 5 million (CI 2.9–8.6 million) during the 2010–2011 season while the number of averted hospitalizations ranged from a
low of 7,700 (CI 3,700–14,100) in 2009–2010 to a high of 40,400 (CI 20,800–73,000) in 2010–2011. Prevented fractions varied
across age groups and over time. The highest prevented fraction in the study period was observed in 2010–2011, reflecting
the post-pandemic expansion of vaccination coverage.
Conclusions: Influenza vaccination programs in the US produce a substantial health benefit in terms of averted cases, clinic
visits and hospitalizations. Our results underscore the potential for additional disease prevention through increased
vaccination coverage, particularly among nonelderly adults, and increased vaccine effectiveness, particularly among the
elderly.
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Introduction
Since 2010, all persons 6 months of age and older in the United
States have been recommended to receive annual influenza
vaccination, making the U.S the only country with universal
influenza vaccine recommendations [1]. The recommendation for
universal vaccination was made after more than a decade of
incremental expansions in the recommendations to include
individuals at high risk for severe influenza or influenza-associated
complications, or those who might spread infection to high-risk
persons [2]. The health and economic benefits of influenza
vaccination have traditionally been evaluated using vaccine
coverage surveys, by observational studies of vaccine effectiveness
or clinical trials of vaccine efficacy in specific populations [3–13],
or by cost-effectiveness studies of influenza vaccination in certain
groups of people or at certain times, based on data from sporadic
studies [14–20]. These studies have been valuable tools in
establishing the potential impact of influenza vaccines in specific
populations or to monitor program operations. However, no
studies have provided a mechanism for the replicable assessment
of national numbers of cases and hospitalizations that are
prevented by vaccination each year.
Since the ultimate justification for influenza vaccination
programs is that they reduce influenza-associated disease out-
comes, it is desirable to have an approach that describes with
annual regularity the reduced national burden of influenza during
each influenza season. Such an approach would allow for a clear
understanding of the value of influenza vaccination in the U.S.
and would enable us to trace vaccine program performance over
time and within demographic groups. Such data would also
identify areas where improvements would lead to greatest benefits.
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In this paper, we present a national model for estimating the
annual direct impact of influenza vaccination in terms of averted
morbidity in order to better understand the impact of influenza
immunization programs in the United States and the factors that
drive this impact. This method of estimation can be updated
annually, and can be used by public health professionals to
estimate and/or project averted burden using assumptions of
vaccination coverage, effectiveness, and influenza clinical attack
rates. These data can easily be communicated to stakeholders
concerning the value of influenza vaccines.
Methods and Data
1. Methods Overview
1.1 Estimating averted burden. In this paper, burden is
defined in terms of influenza cases, medically attended illnesses,
and hospitalizations (henceforth referred to as ‘‘outcomes’’). We
estimated the averted burden of influenza-related outcomes in
several steps. First, we estimated the number of outcomes that
occurred in each season using existing national surveillance data as
a primary input. We then computed intermediary inputs such as
the rates of influenza illness and influenza hospitalization among
susceptible individuals for each month of each season while
accounting for vaccination coverage, vaccine efficacy, and disease
occurrence, and we used these rates to project the burden of
influenza that would have occurred in the absence of vaccination.
The difference between the estimated number of outcomes with
vs. without vaccination equals the burden averted by vaccination.
Each season’s model was stratified by month to accommodate
time-sensitive patterns of vaccination coverage and disease
occurrence, and was built to reflect the length of each season –7
months for seasons 2005–2006 through 2008–2009 and 2010–
2011 (October through April), and 12 months during the 2009
H1N1 pandemic (May 2009 through April 2010). Averted burden
was estimated for four age categories: 6 months-4 years old, 5–19
years old, 20–64 years old, and 65 years and older. This approach
only estimates the direct effects of vaccination to vaccinated
persons, and does not reflect how the underlying attack rates and
disease transmission patterns would have changed in the complete
absence of vaccination; the indirect impact of vaccination (the
additional outcomes that may have been averted by decreasing the
overall disease infectivity through vaccination) is therefore
excluded from the estimates. A detailed methods description is
available in Appendix S1.
Confidence intervals for the reported results were estimated
using a Monte Carlo algorithm, drawing values from sampling
distribution of the input variables used in the model. Additional
details about these sampling distributions are given in Appendix
S1.
1.2 Estimating the prevented fraction. While the number
of averted outcomes each season depends directly on vaccination
coverage and vaccine effectiveness during that season, it also
depends on the influenza attack rate – i.e., seasons with high attack
rates will result in a higher number of averted outcomes assuming
the same rate of vaccination coverage. Therefore, we present
averted influenza burden not only in terms of absolute numbers,
but also in terms of the prevented fraction. We define the
prevented fraction as the proportion of averted outcomes out of
potential outcomes in the absence of vaccination. During each
influenza season, the prevented fraction is the same across
outcomes (cases, medically-attended cases, and hospitalizations)
because the number of cases and MA cases were calculated as
proportions of the estimated number of hospitalizations each
season.
2. Data Sources
2.1 Rates of influenza-associated hospitalization. We
used data on the rates of reported influenza-associated hospital-
izations from CDC’s Emerging Infections Program (EIP) to
estimate the annual number of influenza hospitalizations and
illnesses from 2005 to 2011 (both summarized in Table 1).
Although total annual estimates of influenza hospitalizations have
been reported in the literature for multiple seasons prior to 2001
[21], the EIP is the only data source that provides timely real-time
tracking of influenza hospitalizations in the U.S. as each season
progresses, allowing us to reconstruct the baseline shapes of recent
seasons’ epidemiological curves. The EIP conducts surveillance for
laboratory-confirmed influenza-related hospitalizations in both
children and adults in 60 counties covering 12 metropolitan areas
of 10 states (approximately 22 million people). Using the EIP’s
unique aspect of month-specific and age-specific hospitalization
reporting, we obtained estimates of the reported rates of influenza
hospitalization across 4 age groups for the six most recent seasons
with complete EIP data.
Since EIP records only hospitalizations confirmed by influenza
laboratory test, we needed to account for underreporting.
Underreporting occurs when a person truly hospitalized with
influenza is not tested for influenza, or when the test does not
detect influenza due to the sensitivity of the type of test used or its
timing. To account for underreporting, we adjusted the EIP
estimate by applying a hospitalization underreporting multiplier.
Reed et al. (2009) estimated that during the 2009 H1N1
pandemic, every reported influenza hospitalization represented
2.7 total hospitalizations (95% confidence interval (CI) 1.7–4.5)
[22]. Although no estimates of the hospitalization underreporting
multiplier were available for seasonal influenza prior to 2009,
recent evidence indicates that the disparity in hospitalization
underreporting rates between pandemic and non-pandemic
seasons was not very substantial [23]. We assumed that
hospitalization under-ascertainment in the EIP system before the
2009 pandemic occurred at the same rate as it did during the 2009
pandemic, and adjusted the reported EIP hospitalization rates
accordingly by a factor of 2.7 (CI 1.7–4.5) for all seasons.
The estimated number of influenza-associated hospitalizations
derived in this study is comparable to previously reported
estimates for earlier seasons. Thompson et al (2004) estimated
that during 1979–2001 the average seasonal number of influenza-
related pneumonia and influenza hospitalizations was 133,900 (CI
30,757–271,529). In this study, the estimated average seasonal
number of influenza hospitalizations during 2005–2011 is 128,719
(CI 88,431–208,324) (Table 1). Although these estimates were
obtained through different methodologies and for different time
periods, their similarity illustrates the relative consistency in the
results of the respective estimation approaches.
2.2 Rates of influenza illness. We estimated the number of
influenza illnesses in the US population by applying a ratio of cases
to hospitalizations to the number of estimated influenza-associated
hospitalizations. The case-hospitalization ratio is based on data
from the 2009 season as described by Reed et al. (2009) and varies
by age group (Table 1).
2.3 Rate of Medically-Attended (MA) illness. Only a
fraction of persons with influenza illness seek medical care. This
fraction was estimated from two sources, depending on the season.
For the 2009 H1N1 pandemic, we used age-specific estimates of
the percentage of persons with influenza-like illness (ILI) who
reported receiving medical attention for their illness [24]. For all
other seasons, we used data from an earlier study which found that
42% (CI 37.9%–48.5%) of persons with ILI sought medical care
during the 2006–2007 influenza season [25]. Although this pre-
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pandemic estimate is not age-specific and is based on a single
season, it is the only such data point available before the 2009
pandemic. Because of the possible differences in public awareness
and health-seeking behavior during the pandemic, we apply this
estimate to the five non-pandemic seasons.
2.4 Influenza vaccination coverage. We defined the
monthly incremental vaccination coverage (IVC) for influenza as
the proportion of the population that received influenza vaccina-
tion in each month. Monthly IVC estimates by age group were
obtained from the National Health Interview Survey (NHIS)
(Table 1).
2.5 Influenza vaccine effectiveness. Vaccine effectiveness
(VE) is the percentage reduction in risk of influenza illness that is
attributable to vaccination. Seasonal VE is estimated through
clinical trials or observational studies; since estimates of vaccine
effectiveness can vary across different studies for the same season,
we used an aggregate annual VE estimate based on the range of
available VE estimates in the literature for each season [3–13] by
averaging the range of available values and weighting by the
inverse of the variance for each study. For all but the most recent
season in this study, VE estimates that were specific to each age
group were not available. However, there is evidence that the
immunogenic response to the influenza vaccine is decreased
among persons 65 years and older [26–31]. To reflect this, we
made the assumption that VE in the elderly population was 70%
of the VE estimates available for younger age groups (those under
65 years) during seasons when age-specific VE estimates were not
available (2005–2006 through 2009–2010). To further reflect the
Table 2. Estimated number of influenza cases averted by vaccination and the associated prevented fraction, 2005/06–2010/11
influenza seasons (95% confidence interval in parentheses).
Age Influenza season Number of averted cases Prevented fraction (%)
0–4 ‘05–06 281,127 (155,540–491,787) 12.7 (11.4–13.8)
0–4 ‘06–07 317,922 (190,724–522,177) 18.2 (17.9–18.3)
0–4 ‘07–08 478,042 (297,418–769,426) 18 (17.9–18.0)
0–4 ‘08–09 535,981 (334,699–858,070) 20.5 (20.4–20.5)
0–4 ‘09–10 331,452 (147,420–598,180) 5.8 (4.0–6.6)
0–4 ‘10–11 898,531 (555,749–1,455,290) 29.2 (28.6–29.6)
0–4 6–season total 2,843,053 (1,681,549–4,694,930) 15.7 (14.8–16.3)
5–19 ‘05–06 190,363 (102,511–334,862) 5.8 (5.2–6.2)
5–19 ‘06–07 196,522 (108,191–339,485) 8.7 (8.8–8.7)
5–19 ‘07–08 380,403 (234,028–622,070) 9.6 (9.5–9.6)
5–19 ‘08–09 577,803 (360,831–936,431) 12.6 (12.6–12.6)
5–19 ‘09–10 446,237 (208,880–910,431) 2.1 (1.5–2.8)
5–19 ‘10–11 1,223,501 (754,823–1,993,709) 19.3 (19.1–19.6)
5–19 6–season total 3,014,828 (1,769,264–5,136,988) 7.3 (6.7–7.8)
20–64 ‘05–06 280,160 (156,267–476,407) 7.8 (6.8–8.4)
20–64 ‘06–07 259,640 (163,285–415,766) 10.5 (10.5–10.5)
20–64 ‘07–08 892,219 (591,677–1,379,827) 11.2 (11.0–11.2)
20–64 ‘08–09 448,906 (290,791–711,831) 12.6 (12.6–12.6)
20–64 ‘09–10 490,901 (252,077–868,192) 2 (1.5–2.3)
20–64 ‘10–11 1,635,765 (1,059,380–2,562,763) 13.7 (13.0–14.1)
20–64 6–season total 4,007,591 (2,513,477–6,414,786) 7.4 (6.9–7.7)
65+ ‘05–06 548,659 (303,817–959,082) 17.4 (14.7–19.5)
65+ ‘06–07 284,101 (175,790–458,439) 20.8 (20.7–21.0)
65+ ‘07–08 1,307,926 (867,477–2,011,677) 20.4 (20.1–20.6)
65+ ‘08–09 263,913 (162,638–427,898) 21.3 (21.2–21.3)
65+ ‘09–10 55,178 (27,284–105,159) 2.4 (1.9–2.9)
65+ ‘10–11 1,274,682 (500,228–2,597,822) 21.7 (12.9–28.2)
65+ 6–season total 3,734,459 (2,037,234–6,560,078) 18.4 (15.3–20.7)
All ages ‘05–06 1,300,309 (718,135–2,262,138) 10.6 (9.3–11.6)
All ages ‘06–07 1,058,185 (637,990–1,735,867) 13.5 (13.5–13.6)
All ages ‘07–08 3,058,590 (1,990,600–4,783,002) 14.5 (14.4–14.6)
All ages ‘08–09 1,826,602 (1,148,959–2,934,230) 15.2 (15.1–15.2)
All ages ‘09–10 1,323,768 (635,661–2,481,963) 2.5 (1.8–3.0)
All ages ‘10–11 5,032,478 (2,870,179–8,609,584) 18.5 (16.0–20.3)
All ages 6–season total 13,599,931 (8,001,525–22,806,782) 10.2 (9.2–10.9)
doi:10.1371/journal.pone.0066312.t002
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uncertainty of this assumption we performed sensitivity analyses
where the VE among persons 65 and older was assumed to be,
alternatively, 40% or 80% of the VE among younger populations.
Results
Influenza vaccination averted approximately 13.6 (CI 8.0–22.8)
million illnesses, 5.8 (CI 3.4–10.1) million medical visits, and
112,900 (CI 65,000–191,500) influenza-related hospitalizations
during the 6-year period (Tables 2, 3, 4). The largest number of
averted cases occurred during the most recent season of the study
period, 2010–2011, when 5.0 (CI 2.9–8.6) million influenza cases,
2.1 (1.2–3.7) million medical visits, and 40,400 (CI 20,800–73,100)
hospitalizations were prevented by vaccination, corresponding to a
prevented fraction of 18.5% (CI 16.0%–20.3%). The season with
the lowest number of averted outcomes was 2006–2007, when
approximately 1.1 (CI 0.6–1.7) million cases were averted. The
relatively low number of averted outcomes in 2006–2007 reflects
the low intensity of the season, and the fact that fewer cases can be
prevented when the underlying incidence is low; indeed, the 2006–
2007 season had the lowest attack rate among persons under 65 of
all seasons in our study, as shown by the hospitalization rates in
Table 1. Despite having the lowest number of averted cases, the
2006–2007 season outperformed the previous season in terms of
the prevented fraction, reflecting the season’s improvement in
vaccine coverage and vaccine effectiveness (13.5% (CI 13.5%–
Table 3. Estimated number of medically-attended (MA)
influenza cases averted by vaccination, 2005/06–2010/11
influenza seasons (95% confidence interval in parentheses).
Age Influenza season Number of averted MA cases
0–4 ‘05–06 118,073 (66,081–214,000)
0–4 ‘06–07 133,527 (80,762–226,718)
0–4 ‘07–08 200,777 (124,972–336,387)
0–4 ‘08–09 225,112 (141,780–376,297)
0–4 ‘09–10 222,073 (98,566–401,175)
0–4 ‘10–11 377,383 (234,575–634,163)
0–4 6–season total 1,276,945 (746,735–2,188,741)
5–19 ‘05–06 79,952 (43,564–146,080)
5–19 ‘06–07 82,539 (45,810–146,801)
5–19 ‘07–08 159,769 (98,392–269,500)
5–19 ‘08–09 242,677 (151,815–409,603)
5–19 ‘09–10 227,581 (106,135–465,664)
5–19 ‘10–11 513,870 (318,802–862,821)
5–19 6–season total 1,306,389 (764,520–2,300,470)
20–64 ‘05–06 117,667 (66,351–207,808)
20–64 ‘06–07 109,049 (69,214–181,233)
20–64 ‘07–08 374,732 (249,901–603,264)
20–64 ‘08–09 188,540 (121,493–311,448)
20–64 ‘09–10 181,633 (92,823–322,744)
20–64 ‘10–11 687,021 (447,295–1,119,398)
20–64 6–season total 1,658,643 (1,047,078–2,745,894)
65+ ‘05–06 230,437 (128,709–417,093)
65+ ‘06–07 119,322 (74,175–200,011)
65+ ‘07–08 549,329 (367,817–883,761)
65+ ‘08–09 110,844 (68,586–186,931)
65+ ‘09–10 30,900 (15,220–59,141)
65+ ‘10–11 535,366 (213,902–1,122,578)
65+ 6–season total 1,576,198 (868,410–2,869,516)
All ages ‘05–06 546,130 (304,706–984,981)
All ages ‘06–07 444,438 (269,962–754,764)
All ages ‘07–08 1,284,608 (841,082–2,092,912)
All ages ‘08–09 767,173 (483,674–1,284,279)
All ages ‘09–10 662,187 (312,744–1,248,725)
All ages ‘10–11 2,113,641 (1,214,575–3,738,960)
All ages 6–season total 5,818,175 (3,426,742–10,104,621)
doi:10.1371/journal.pone.0066312.t003
Table 4. Estimated number of influenza hospitalizations
averted by vaccination, 2005/06–2010/11 influenza seasons
(95% confidence interval in parentheses).
Age Influenza season Number of averted hospitalizations
0–4 ‘05–06 1,960 (1,084–3,429)
0–4 ‘06–07 2,216 (1,330–3,640)
0–4 ‘07–08 3,333 (2,073–5,364)
0–4 ‘08–09 3,737 (2,333–5,982)
0–4 ‘09–10 2,311 (1,028–4,170)
0–4 ‘10–11 6,264 (3,874–10,146)
0–4 6–season total 19,821 (11,723–32,731)
5–19 ‘05–06 522 (281–918)
5–19 ‘06–07 539 (297–931)
5–19 ‘07–08 1,043 (642–1,706)
5–19 ‘08–09 1,584 (989–2,568)
5–19 ‘09–10 1,224 (573–2,496)
5–19 ‘10–11 3,355 (2,070–5,467)
5–19 6–season total 8,266 (4,851–14,085)
20–64 ‘05–06 1,890 (1,054–3,215)
20–64 ‘06–07 1,752 (1,102–2,805)
20–64 ‘07–08 6,020 (3,992–9,311)
20–64 ‘08–09 3,029 (1,962–4,803)
20–64 ‘09–10 3,312 (1,701–5,858)
20–64 ‘10–11 11,038 (7,148–17,293)
20–64 6–season total 27,042 (16,960–43,285)
65+ ‘05–06 8,484 (4,698–14,830)
65+ ‘06–07 4,393 (2,718–7,089)
65+ ‘07–08 20,225 (13,414–31,107)
65+ ‘08–09 4,081 (2,515–6,617)
65+ ‘09–10 853 (422–1,626)
65+ ‘10–11 19,711 (7,735–40,170)
65+ 6–season total 57,746 (31,502–101,439)
All ages ‘05–06 12,856 (7,118–22,392)
All ages ‘06–07 8,900 (5,446–14,466)
All ages ‘07–08 30,621 (20,121–47,487)
All ages ‘08–09 12,431 (7,800–19,970)
All ages ‘09–10 7,700 (3,723–14,151)
All ages ‘10–11 40,367 (20,827–73,075)
All ages 6–season total 112,875 (65,036–191,540)
doi:10.1371/journal.pone.0066312.t004
Influenza Illness and Hospitalizations Averted
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13.6%) prevented fraction in 2006–2007 vs. 10.6% (CI 9.3%–
11.6%) in 2005–2006, Table 2).
Before the 2009 pandemic, the prevented fraction increased
over time from 10.6% (CI 9.3%–11.6%) in 2005–2006 to 15.2%
(CI 15.1%–15.2%) in 2008–2009 (Figure 1) even as the number of
averted outcomes fluctuated (Figure 2). The 2009 pandemic
represented a break in this trend with a prevented fraction of 2.5%
(CI 1.8%–3.0%). This decrease in the prevented fraction reflected
the early timing of pandemic–associated disease relative to vaccine
availability, despite a relatively high vaccine effectiveness con-
ferred by the pandemic vaccine. Despite the lag in vaccination, the
high attack rate associated with the 2009 H1N1 pandemic virus in
younger populations resulted in an overall number of averted cases
(1.3 (CI 0.6–2.5) million) that was comparable in magnitude
relative to earlier seasons; in fact, the number of averted cases
among adults aged 20–64 may have been higher during the
pandemic than during the preceding season (Table 2).
Over the study period, the largest total number of averted
outcomes occurred among adults 20–64 years of age, the largest
age group in the study. Nevertheless, the 6-year average prevented
fraction in this age group tended to be among the lowest at 7.4%
(CI 6.9%–7.7%), similar to that in children aged 5–19 (Table 2).
Before the 2009 pandemic, the prevented fractions were highest
for persons 65 and older. During the 2009 pandemic, the highest
prevented fraction occurred among children under 4 at 5.8% (CI
4.0%–6.6%), and remained higher than all other age groups in the
post-pandemic 2010–2011 season as well, at 29.2% (CI 28.6%–
29.6%) (Figure 1).
When estimating the impact of vaccination among the elderly,
we accounted for the reduced effectiveness of the vaccine among
the elderly by assuming that in seasons for which age-specific VE
estimates were not available (all seasons except 2010/11), the VE
for the elderly was a fraction the non-elderly VE. We set this
fraction to 70% in the main analysis, and reflected the uncertainty
of this assumption by performing a sensitivity analysis where we
assumed that the elderly VE was, alternatively, 40% and 80% of
the non-elderly VE. The results of this sensitivity analysis are
shown as supplementary material in Table S1. We found that
while the number of averted outcomes among the elderly was
indeed higher at higher levels of VE, the overall number of averted
Figure 1. Prevented fraction of influenza cases, by age group, 2005/06–2010/11 influenza seasons.
doi:10.1371/journal.pone.0066312.g001
Figure 2. Number of averted influenza cases, by age group, 2005/06–2010/11 influenza seasons.
doi:10.1371/journal.pone.0066312.g002
Influenza Illness and Hospitalizations Averted
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outcomes in the entire population (all ages) was not substantially
sensitive to variations in the elderly VE (Table S1), reflecting the
relatively small proportion of elderly in the population.
Discussion
While the vaccine produced benefits each season, the number of
influenza-associated outcomes averted by vaccination fluctuated
across age groups and seasons (Figure 2), reflecting the interplay of
seasonal differences in vaccination coverage, vaccine effectiveness,
and influenza attack rate. Of these impact determining factors, the
attack rate is the only one not subject to human intervention, so
from an impact evaluation standpoint it may be appropriate to
assess impact net of its influence (seasons with higher attack rates
could be associated with more averted cases simply because more
people are susceptible to becoming ill, so that a greater number of
illnesses could be prevented with the same level of vaccination and
vaccine effectiveness). Calculating the prevented disease fraction
instead of the number of averted cases can useful for describing the
impact of vaccination programs because it controls for the relative
severity of different seasons. The prevented fraction can also
present a different pattern of impact over time than the number of
averted outcomes alone – a pattern which more clearly reflects the
benefits of increased vaccination coverage. The population-level
benefits of increased vaccination become apparent when compar-
ing the generally rising trend in vaccination coverage over time
(Table 1) to the trend in the prevented fraction over time (Table 2)
for each age group; this comparison shows that a greater fraction
of disease was prevented as greater fractions of the population
became vaccinated.
The prevented fraction during the 2009 pandemic was lower
than during other seasons, highlighting the importance of the
timing of vaccination relative to disease occurrence. While
vaccination still prevented a considerable number of outcomes
during the pandemic, the relatively late availability of the vaccine
relative to the timing of pandemic disease in 2009–2010 resulted in
a comparatively low prevented fraction during that year. Across
age groups, the prevented fraction during the 2009 pandemic was
highest among children aged 0–4, indicating that the priority
schedule for vaccinating younger persons may have yielded a
health benefit (Figure 1).
The increase in the prevented fraction during the 2010–2011
season relative to earlier seasons demonstrates how increases in
vaccination coverage can drive substantial improvements in the
impact of vaccination. Likely due to raised post-pandemic
awareness about influenza, overall vaccination in 2010–2011
increased compared to both pandemic and pre-pandemic levels
(Table 1). In 2010, a higher proportion of vaccinations also
occurred earlier in time than during previous seasons, with
relatively higher vaccination rates in the months of August and
September [32]. The increases in vaccination coverage across all
age groups that occurred in the season after the 2009 pandemic
produced the largest vaccine impact observed over the 6-year
study period both in terms of prevented fraction and number of
averted cases (Figures 1 and 2).
Vaccination coverage tends to be lowest among adults aged 20–
64, as many persons in this age group were not targeted for
vaccination until the universal recommendations were issued in
2010. Because of the disproportionately large size of this
population subgroup, increasing vaccination coverage among the
nonelderly adults is likely to result in a large increase in the
number of averted cases. While vaccination coverage among the
elderly has been traditionally high (Table 1), the comparatively
lower effectiveness of the influenza vaccine in this age group
reduced the benefits that such high levels of vaccination could
have otherwise produced. Improving vaccine effectiveness among
the elderly would have an additional impact on averted influenza-
associated outcomes, especially hospitalizations, which occur at
much higher rates in this age group.
Our study is subject to a number of limitations, most of which
are associated with the choice of input values used in the model.
First, vaccine coverage data were obtained from NHIS and were
based on self-report; some selection bias may remain even after
weighting adjustments for survey nonresponse, and coverage data
did not indicate the number of doses received. Second, due to lack
of pre-pandemic data, we assumed that the hospitalization
underreporting multiplier was the same during all nonpandemic
seasons as during the 2009 pandemic. Since increased surveillance
and awareness during the pandemic may have contributed to
higher testing and higher hospitalization rates than during
seasonal epidemics, using the underreporting multiplier calculated
from 2009 data may result in conservatively low estimates of
hospitalizations for non-pandemic seasons. However, recent
studies have confirmed that these multipliers are similar between
pandemic and non-pandemic periods [33]. Third, data on the
variability of vaccine effectiveness among different age groups are
limited. Similarly, data on the fraction of ILI that were medically
attended in non-pandemic seasons were not available by season
and age and thus a constant rate was assumed.
Vaccination against influenza has a substantial annual impact
on the burden of disease in the United States. The study
demonstrates that improvements in vaccination coverage among
non-elderly persons and improvements in vaccine effectiveness
among the elderly will lead to greater gains in program
effectiveness. These data can be used to estimate the economic
impact of vaccination programs on the national level. In addition,
the model can estimate the effect of current policies on reducing
disease among vulnerable groups such as pregnant women, and
can be used to predict the impact of program improvements or
alternative vaccination policies. Finally, because this study focuses
on estimating the direct impact of vaccination only, further
refinements that include estimation of the indirect impact of
vaccination would yield a more complete estimate of the value of
influenza vaccination programs in the United States.
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